Morgan Stanley Knock-Out PGR/ DE000ME8Z696 /
28/08/2024 21:45:49 | Chg.+0.31 | Bid22:00:35 | Ask22:00:35 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
5.93EUR | +5.52% | - Bid Size: - |
- Ask Size: - |
Progressive Corporat... | 182.0002 USD | 31/12/2078 | Call |
GlobeNewswire
19/08
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
GlobeNewswire
19/08
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire
15/08
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
14/08
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene ...
GlobeNewswire
14/08
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
GlobeNewswire
13/08
Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire
12/08
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Newsfile Corp
12/08
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
08/08
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15,...
GlobeNewswire
07/08
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Sus...
GlobeNewswire
07/08
AGS Unveils its Latest Table Innovation Bonus Spin Xtreme for Poker Rooms and an Exciting New Lineup...
GlobeNewswire
07/08
Team, Inc. Announces Timing of Second Quarter Earnings Release and Conference Call
GlobeNewswire
06/08
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy)...
GlobeNewswire
06/08
Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, fo...
GlobeNewswire
05/08
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted...